Osteogenesis imperfecta (OI) is a heterogeneous group of genetic disorders that affect connective tissue integrity. The hallmark of OI is bone fragility, although other manifestations, which include osteoporosis, dentigenesis imperfecta, blue sclera, easy bruising, joint laxity and scoliosis, are also common among OI patients. The severity of OI ranges from prenatal death to mild osteopenia without limb deformity. Most forms of OI result from mutations in the genes that encode either the proa1or proa2 polypeptide chains that comprise type I collagen molecules, the major structural protein of bone. Treatment depends mainly on the severity of the disease with the primary goal to minimize fractures and maximize function. Current treatments include surgical intervention with intramedullarly stabilization and the use of prostheses. Pharmacological agents have also been attempted with limited success with the exception of recent use of bisphosphonates, which have been to shown to have some effect. Since OI is a genetic disease, these agents are not expected to alter the course of the collagen mutations. Cell and gene therapies as potential treatments for OI are therefore currently being actively investigated. The design of gene therapies for OI is however complicated by the genetic heterogeneity of the disease and by the factor that most of the OI mutations are dominant negative where the mutant allele product interferes with the function of the normal allele. The present review will discuss the molecular changes seen in OI, the current treatment options and the gene therapy approaches being investigated as potential future treatments for OI.
Introduction
Potential application of gene therapy for the treatment of a variety of orthopedic-related conditions is currently an active area of investigation. 1, 2 The present review discusses gene therapy approaches being investigated for osteogenesis imperfecta (OI) and the obstacles that will need to be overcome for successful development of gene therapies for OI. The design of gene therapies for OI is challenging because of the inherent heterogeneity of the disease. Over 100 different mutations have been identified in the genes that encode the proa1(I) and the proa2(I) polypeptide chains that comprise the type I collagen molecules. 3, 4 The majority of these mutations are dominant negative; thus, gene therapy approaches for OI will require silencing of the expression of the genes that encode abnormal collagen alleles before replacement of the mutated gene. The repetitive nature of the collagen amino-acid sequence, however, creates difficulties in the design of the antisense gene therapy approaches that only target the expression of the abnormal collagen alleles.
Classification of OI subtypes
The incidence of OI ranges from one per 10 000 to one per 20 000 live births. 5, 6 Although bone is the most affected tissue in all of the OI phenotypes, other tissues rich in type I collagen, for example, skin, tendon, ligament and dentin are also severely affected. The earliest classification system of OI was based on the age of onset of clinical manifestations. Patients having fractures occurring at birth were classified as congenita and those with fractures later in life were classified as tarda. 3, 7 The most widely used system, however, was developed in 1979 by Sillence. 8 This system is based on clinical, genetic and radiographic findings. Although widely accepted, many patients with OI still do not readily fall into the four classes of Sillence's classification due to the broad spectrum of molecular abnormalities resulting in OI. This has prompted some investigators to propose existence of other subtypes of OI, namely type V, VI and VII. [9] [10] [11] These new subtypes are believed not to be directly associated with type I collagen mutations but other yet unidentified macromolecules. Type I OI is the most common and the mildest form (Table 1) . It is an autosomal dominantly inherited form that is characterized by mild bone fragility with fractures occurring after moderate trauma, as well as blue sclera and conductive hearing loss. It is subdivided into types A and B based on the presence of dentigenesis imperfecta. The genetic mutation is such that synthesis of normal type I collagen occurs, but in reduced amounts due to a null a1(I) allele. 12, 13 Type II OI is the most severe form with most resulting in prenatal fatality. Infants with Type II OI experience intrauterine fractures, intracranial hemorrhage following vaginal delivery and succumb to death shortly after birth. 3, 6 Type II OI usually results from new mutations in the genes that encode the polypeptide chains of type I collagen. Death usually results from pneumonia or respiratory insufficiency secondary to decreased thoracic size. Type III OI is an autosomaldominant disorder characterized by moderate to severe bone fragility. Spontaneous mutations in some of the patients with OI type III can also not be ruled out. Intrauterine fractures are characteristic along with bone deformity, short stature and triangular faces. This form of OI is sometimes referred to as progressively deforming, because, the incidence of fractures among these patients increases with age. The patients usually require multiple orthopedic procedures throughout life. Type IV has some similarities to Type I, but with more severe osseous involvement and less extraskeletal abnormalities. The genetic defects in OI Types II, III and IV result in the synthesis of structurally abnormal proa1 or proa2 chains of type I collagen. The defective procollagen molecules are either intracellularly or extracellularly degraded or they lead to the formation and deposition of abnormal collagen fibrils in connective tissues.
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Molecular abnormalities
Despite the wide range of clinical manifestations observed in OI, most cases of OI result from mutations that affect the genes that encode the proa1 and proa2 polypeptide chains that comprise the type I collagen molecules. Collagen, of which there are several types, is a fibrous, structural protein found in all multicellular organisms. Presently, more than 20 distinct types of collagens have been identified. 3, 17 Type I collagen is the most abundant type of collagen and is widely distributed in almost all connective tissues with the exception of hyaline cartilage. It is the major protein in bone, skin, tendon, ligament, sclera, cornea and blood vessels. Type I collagen comprises approximately 95% of the entire collagen content of bone and about 80% of the total protein present in bone. 18 Type I collagen is composed of two identical a1 polypeptide chains and one similar but distinct a2 polypeptide chain; the three chains are twisted around each other like a stranded rope. The genes that encode the a 1 and a 2 polypeptide chains are sometimes referred to as COL1A1 and COL1A2, respectively. Each polypeptide chain is composed of about 1000 amino acids arranged in uninterrupted repeats of Gly-X-Y triplet where X can be any other amino acid but is usually a proline and Y is often a hydroxyproline. Glycine is an absolute requirement in every third position, because it is the smallest amino acid that can occupy the limited space in the center of the triple helix. Each a chain is synthesized in a precursor form called proa chain that consists of globular extension peptides at the amino-and the carboxy-terminal ends. Proa chains assemble to form a precursor form of collagen called procollagen. Extracellular processing by specific enzymes removes the carboxy-and the amino-terminal globular domains to generate collagen molecules. The collagen molecules self-assemble in a quarter staggered array, undergo intermolecular crosslinking and form fibrils ( Figure 1 ). Mutations in COL1A1 and COL1A2 genes that affect the amino-acid sequence in the helical domain of one of the proa chains, resulting in a complete lack of type I collagen production, or a substitution of the conserved glycine residue with an amino acid with a bulky side chain, result in OI. 14, 16, 19 The genotypephenotype relationship is not clearly understood, but what is clear is that bone fragility may result from either insufficient matrix synthesis or the accumulation of defective collagen molecules in the extracellular matrix. [14] [15] [16] Defects in collagen processing can also produce other types of connective tissue disorders, such as some forms of Ehlers-Danlos syndromes.
Clinical manifestations
The clinical expression of OI traverses a broad spectrum from mild osteoporosis to prenatal death. Musculoske- In general, the earlier the fractures occur in life, the more severe the disease. The lower limbs are more commonly involved, as they are more susceptible to trauma. Femural fractures are the most common fractures of long bones, with the fracture located usually at the convexity of the bone. They are usually transverse and minimally displaced ( Figure 2 ). Multiple fractures within the same bone often occur as a result of the severe angulation in which it heals and because of disuse atrophy, both of which make it more susceptible to a second fracture. Bowing of the long bones results from the multiple transverse fractures and the pulling of strong muscles. Cranial deformity is also common. There is flattening of the posterior cranium with a bulging calvarium and a triangular-shaped face. In some OI patients, the teeth are also severely affected; they are extremely brittle, breaking easily and susceptible to caries. When the teeth are affected in OI patients, this is referred to as dentigenesis imperfecta and has been used by Sillence to subclassify Type I and Type III OI. 20 Extraskeletal findings include blue sclera in some OI patients and it is a hallmark characteristic of OI Type I.
Deafness occurs in approximately 40% of Type I OI patients and in a lower percentage of Type IV OI.
Current orthopedic management
The principles for management of OI are to maximize function and minimize fracture occurrence. Treatment plans are designed to correct the existing deformities, and to avoid future deformities by combining state-ofthe-art fracture care with prophylactic management of brittle bones using internal supports and external orthotic devices. A multidisciplinary approach including the orthopedic surgeon, pediatrician, physical therapist and social worker can maximize the function of the child and provide education to family. This can allow independent function and improved social integration. The level of maximum function varies depending on the severity of the disease. The extent of operative and nonoperative treatment required varies from patient to patient. The treatment required also varies with the age of the patient. In younger children, fractures occur due to falls because of lack of coordination and adequate postural strength. As a child becomes older, the incidence of fractures goes down but other complications of OI begin to manifest themselves, such as scoliosis or hearing loss. Surgical correction of severe deformities that interfere with a patient's functional status may be used. Such interventions include osteoclasis, intramedullarly nailing, osteotomies or a combination of these techniques. 
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Elongating and nonelongating intramedullarly rods have also been used with similar results. 21 
Pharmacological therapies
In addition to orthopedic management, pharmacological agents have been attempted although with little success. Some examples of these agents include calcium, fluoride, calcitonin, anabolic steroids and magnesium. 6 Growth hormone has also been tried as a means of increasing growth among OI patients. 22, 23 Drugs whose initial indication was for osteoporosis have also been investigated. Recently, however, the use of bisphosphonates in children with OI has been shown to have some beneficial effects. [24] [25] [26] Bisphosphonates are compounds that bind to bone matrix and in so doing inhibit osteoclastic activity by inducing apoptosis of the cells. These agents are currently being used in the treatment of osteoporosis in postmenopausal women. 27 Treatment is aimed at reducing bone resorption, which has been found to be abnormally high by histomorphometric and biochemical studies. 28, 29 In a comprehensive clinical trial, a 2-year cyclic administration of pamidronate to OI patients over 3 years of age showed a marked reduction in bone pain as early as 1 week after initiating therapy, as well as reduction in the incidence of fractures. 24 Decreased osteoclastic activity was indicated by a reduction in serum levels of calcium, phosphate and alkaline phosphatase. Radiographic evidence of increased bone density above normal age-related increases was noted over the 2-year treatment period as measured by X-ray absorptiometry. Other radiographic evidence of increased bone density included increased vertebral body height, formation of dense lines and increased cortical width. Subsequent administration of pamidronate in OI children under the age of 2 years demonstrated a dramatic reduction in the fracture rate, increase in bone mineral density and an increase in vertebral height. 25 Parallel studies in a mouse model of OI using alendronate demonstrated a reduction in the number of fractures and an increase in bone mineral density in the treated animals. The bones of the treated animals were, however, reported to exhibit a persistence of calcified cartilage and the femurs tended to be short, suggesting that perhaps there may be retardation in growth of the treated animals. 30 Although these studies show promising possibilities for the use of bisphosphonates in the treatment for OI, these agents do not address the collagen mutations that lead to the OI disease.
Cell and gene therapies
Although the treatment options available for OI patients have improved lifestyle, there is still no cure for OI. Novel approaches using bone marrow-derived mesenchymal stem cells or cells referred to as bone marrow stromal cells by some investigators, and gene therapy are currently being investigated as potential treatments for OI. Gene therapy for OI treatment is complicated by the genetic heterogeneity of the disease and the fact that over 100 different mutations have been identified in the genes that code for the proa1 and proa2 chains. 3, 4 Most OI mutations are dominant negative, the most common being point mutations that substitute the conserved glycine in the helical region of either proa1 or proa2 chains of type I collagen with charged amino acids or amino acids having bulky side chains. 3, 14, 16 Proa chains with such mutations are incorporated in the triple helical assembly with the normal chains and in so doing they destabilize the triple helical conformation of the collagen molecules. The assembled defective collagen molecules may either undergo intracellular or extracellular degradation or are deposited in the extracellular matrix in the form of defective collagen fibrils. 3, 14 Replacement of the mutant collagen allele by gene therapy approach in this situation may therefore not be beneficial.
Cell therapy
The cell therapy approach aims to overcome the problems associated with dominant-negative OI mutations by supplying cells that would give rise to osteoblasts, the bone-forming cells, to replace the cells that synthesize abnormal collagen chains. Osteoblasts are terminally differentiated, nonproliferating cells with a limited lifespan. Osteoblasts arise from mesenchymal stem cells that reside in the bone marrow whereas the osteoclasts, the cells that are involved in bone resorption, are derived from hemopoietic lineage. 31, 32 The ability for bone to regenerate is attributed to quiescent stem cells in bone that undergo proliferation and differentiation. [33] [34] [35] [36] The rationale for cell therapy is that mutant osteoblasts as they turnover or become quiescent can be replaced by normal osteoblasts derived from the transplanted progenitors. In addition, since the transplanted cells are stem cells, they will self-renew and thus provide treatment for life. Normal transplanted cells may also possess survival advantage over the endogenous cells because they synthesize normal matrix. 37 The above hypotheses were initially tested in mice. Bone marrow-derived mesenchymal stem cells or stromal cells harvested from transgenic mice expressing a human truncated or minigene for proa1 (I) collagen were infused into irradiated mice. 37 PCR assays to follow the fate of the cells expressing the minigene were used to locate the cells in different tissues of the recipient mice. At 1-5 months after cell infusion, 1.5-12% of the cells in various tissues including bones of the recipient mice were reported to be from the donor. 37 In subsequent studies, bone marrow stromal cells were harvested from wild-type mice and infused into the transgenic mice expressing the human collagen proa1 (I) minigene. At 2 1 2 months after cell infusion, 4-19% of the cells in various tissues including the bones of the recipient mice were reported to be of donor origin. 38 Several other investigators have reported similar findings in murine, sheep and baboon animal models. [39] [40] [41] [42] Using similar approaches as above but with bettercharacterized mouse bone marrow stromal cells, the current authors have shown that cells infused into mouse femurs persist in bone. Murine adherent marrow stromal cells were established using standard methods and were then marked by transduction with a retrovirus carrying the LacZ marker gene. The marked cells were evaluated for bone formation in vivo by subcutaneous implantation of ceramic cubes loaded with the cells in SCID mice.
Analysis of the ceramic cubes at different time points
Gene therapy and osteogenesis imperfecta C Niyibizi et al demonstrated that the isolated cells were capable of differentiating into chondrocytes and could also form bone in vivo. 39, 43 Infusion of the cells into immunecompetent mice demonstrated that the cells colonized the bones of the recipient mice and differentiated into osteoblasts in vivo. 39, 43 Prompted by the murine studies, human clinical trials in children with severe OI were initiated by Horwitz and colleagues using whole marrow harvested from leukocyte antigen (HLA) matched donors. Five children were enrolled in the trial and subjected to irradiation followed by bone marrow transplantation from matched donors. Three of the children who received bone marrow transplantation were documented to exhibit donor osteoblasts in their bones 3 months after cell transplantation. 44 The children who were shown to possess osteoblast engraftment after 6 months of marrow infusion were reported to exhibit an increase in body length. The patients also gained 45-77% of total bone mineral content from the baseline values and also exhibited a reduction in fracture rates. The authors concluded that bone marrow transplantation from normal donors to OI patients might be of benefit in OI. [44] [45] [46] The number of donor cells that engrafted in marrow recipients was however very small. At 3 months after bone marrow transplantation, only 1.5-2% of the cells in trabecular bone of the cell recipients were estimated to be of the donor origin. How such small numbers of cells can contribute to the observed major changes and impressive improvement in the bones of the OI patients who received cell transplantation, however, remains unclear.
Antisense gene therapy approaches
Because most of OI mutations are dominant negative as mentioned above, the classical gene therapy approach of gene supplementation may not be of benefit for OI treatment. Gene replacement may however be used as a supplement or in conjunction with antisense gene therapy. [47] [48] [49] [50] [51] Most efforts in the investigation of gene therapy for OI are directed toward developing methods to silence the expression of the abnormal collagen allele thereby converting a severe form of OI into a mild one. 51 An antisense RNA or DNA molecule complimentary to the mRNA for the mutant protein binds to the target mRNA to prevent its translation. Oligodeoxynucleotides are short pieces of DNA that are designed to bind tightly to the target RNA. The paired mRNA/DNA hybrids are then degraded intracellularly by the RNase. This approach was initially tested in mice expressing the human proa1(I) minigene. Transgenic mice expressing an antisense gene directed against the human proa1(I) minigene were generated and were then crossed with the transgenic mice expressing the human collagen minigene. The data demonstrated that in mice that inherited both genes, the incidence of the lethal fragile bone phenotype was reduced from 92 to 27%. 52 Subsequent studies using the same approach, but in fibroblasts harvested from a patient with a case of OI type IV, demonstrated that use of short deoxyribonucleotides to target the mutant RNA was effective in suppressing the expression of the mutant RNA but expression of the normal RNA was also suppressed to unacceptable levels. 53 This is because of the repetitive nature of the collagen amino-acid sequence that requires every third residue be glycine.
Designing deoxynucleotides that recognize sequences differing in one base change is not a simple task. To achieve allele-specific suppression, use of ribozymes in gene silencing is being investigated. Ribozymes are short RNA molecules composed of a hairpin loop with two binding arms. The binding arms are designed to be complementary to the mutant RNA. Ribozymes target the mutant RNA so that the catalytic core of the hairpin loop is opposite the cleavage site on the target mRNA. 54 Using this approach, hammerhead ribozymes directed against normal and mutated mouse COL1A1 gene transcripts demonstrated that ribozymes were able to recognize and cleave specific targets even in the presence of high levels of nontarget RNA. 55, 56 In these experiments, the ribozymes were, however, targeted to the mutant RNA at the mutation site. The limitations of this approach, as suggested by Forlino and Marini, 47 are that only a relatively low percentage of known collagen mutations generate ribozyme cleavage sites and enormous amounts of time would be required to evaluate the specificity of each ribozyme targeted to each individual mutation. Studies by Millington-Ward et al [48] [49] [50] have, however, shown that it may be possible to design mutation-independent strategies to suppress mutant alleles. In one particular study, a hammerhead ribozyme was designed to target a common polymorphism within transcripts from the COL1A1 gene. The ribozyme was delivered to the human mesenchymal progenitor cells by transduction with a retroviral vector encoding the ribozyme, and downregulation of the COL1A1 gene was analyzed at the gene and protein levels. Using this approach, about 40-50% suppression of COL1A1 expression both at the RNA and protein levels was demonstrated. 48 Other approaches of gene silencing for OI treatment are being pursued. One particular approach is the use of double-stranded RNA (dsRNA) sometimes referred to as RNA interference (RNAi). This approach has been demonstrated in a number of organisms that include plants, protozoa, nematodes and insects. 57 This approach is currently being investigated for use in the downregulation of collagen gene expression in cells as a potential treatment for OI. 58 In this approach dsRNA for a specific target gene is delivered into cells, the dsRNA then undergoes degradation generating 21-25-nucleotide small interfering RNAs (siRNAs) which initiate degradation of the target RNA. Direct delivery of siRNAs, rather than their dsRNA precursors, into mammalian cells has been shown to be more effective in downregulating specific gene expression. 57 
Gene supplementation approaches for OI
As discussed above, a gene therapy approach directed based upon delivery of a wild-type collagen gene in OI would not be a logical approach without first silencing the expression of the mutant collagen allele. Most OI mutations are dominant negative such that a mutant procollagen chain is made, and this chain then associates with normal procollagen chains to form triple helical molecules that contain abnormal chains. The abnormal Gene therapy and osteogenesis imperfecta C Niyibizi et al procollagen molecules may either undergo intracellular degradation or may assemble into defective collagen fibrils resulting in the deposition of the abnormal collagen fibrils in the extracellular matrix. To overcome this, expression of the mutant allele needs to be eliminated, using the methods described above, before transfer of the normal procollagen gene. Gene supplementation, therefore, would be used in conjunction with antisense gene therapy or some other technology that silences the mutant allele. In addition, since autologous progenitors would be used for ex vivo gene therapy, this would avoid use of irradiation or other forms of marrow ablation of the OI patients before cell transplantation. Gene therapy using a mutation-independent approach by targeting polymorphic sites within procollagen genes may be used in conjunction with the collagen gene supplementation as suggested by Millington-Ward et al.
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In addition, it may be possible to overexpress the normal collagen gene in the OI patients cells to shift the equilibrium toward the formation of normal collagen molecules.
The authors are currently investigating the feasibility of gene supplementation for OI in a mouse model of human OI. The mouse model of OI (oim) possesses a null mutation in which proa2(I) collagen chains are not synthesized. 59 Mice homozygous for the OI murine mutation are deficient in proa2(I) collagen production because of a G deletion at nucleotide 3983 in the carboxyterminal propeptide coding region of the COL1A2 gene. 59 This mutation prevents incorporation of proa2(I) chains into heterotrimers and results in accumulation of a1(I) homotrimers in tissues. These mice exhibit cortical thinning, bowing of long bones, fractures and callus formation characteristic of human OI type III. Although the mice exhibit a mutation that is not typical for most human OI phenotypes, it presents an excellent model for investigating the feasibility of cell and gene therapy for OI using a gene supplementation approach.
Ex vivo gene delivery to bone
To evaluate possibilities for ex vivo gene therapy, and the potential of gene supplementation for OI, bone marrow stromal cells isolated from oim mice were transduced with a retroviral vector expressing human growth hormone; they were then infused into oim mice femurs. 60 The infused cells were shown to express the hormone in vivo as indicted by the presence of the hormone in the serum of the recipient mice. 60 The expression of the hormone was detected up to10 days after cell infusion. The cells that expressed the human growth hormone were recovered from the injected femurs as well as contralateral femurs 6 days after cell infusion. These data suggested that osteoprogenitor cells might be useful targets for the delivery of the therapeutic genes to bone and that the genes can be expressed in bone with high efficiency. Gene therapy and osteogenesis imperfecta C Niyibizi et al According to one strategy, gene supplementation or mutant gene silencing for OI treatment will be performed ex vivo. Autologous mesenchymal stem cells can be harvested from an OI patient, genetically modified in vitro, and then returned to the patient. Previous studies in mice and humans have demonstrated that bone marrow-derived mesenchymal stem cells will migrate to bone when administered systemically. [37] [38] [39] 46 We previously showed that direct injection of the cells into the mouse bone marrow cavity leads to a wide distribution of the cells in different tissues of the host. 39 Since early treatment for OI will be essential, mesenchymal stem cells transduced with therapeutic genes will need to be delivered early during development. We have explored this idea by systemic injection of bone marrowderived mesenchymal stem cells transduced with a retrovirus carrying the e-GFP gene (Figure 3a) , into the superficial temporal vein of the 2-day-old newborn mice using the methods described previously. 61 The data demonstrated that the e-GFP-transduced cells colonized most of the newborn mouse tissues within 5 days after cell injection (Figure 3b, unpublished data) . The highest expression of e-GFP was seen in the liver and lung 5 days after infusion of the cells expressing GFP (Figure 3c ). There were no GFP-positive cells detected in bone at this time period. At 25 days after infusion of e-GFP-positive cells into the newborn mice, however, a larger number of GFP-positive cells were detected in cultured bone fragments of the femurs harvested from the mice that were infused with GFP-positive allogenic bone marrow stromal cells at a neonatal stage (Figure 3d ). These data demonstrate that systemic delivery of the mesenchymal stem cells transduced with therapeutic genes will lead to a wide expression of the genes in vivo, which is a critical element for OI treatment.
The potential of collagen gene replacement as an approach for OI treatment was further evaluated by determining the ability of the bone marrow stromal cells to be transduced with collagen genes and to express the genes with high efficiency in vitro and in vivo. As a proof of concept, an adenoviral vector carrying the murine procollagen a2(I) cDNA was constructed and used to transduce osteoprogenitor cells harvested from oim mice that are deficient in the proa2(I) collagen synthesis. Analysis of the collagen secreted into the medium by the transduced cells demonstrated that the a1(I) and a2(I) chains were synthesized in the correct ratio of 2:1 62 ( Figure 4) . In addition to the expression of the collagen gene in vitro, direct injection of the vector into the skin and femurs of the oim mice demonstrated high expression of the collagen transgene in the skin and femurs of the recipient mice 62 (unpublished data). Although these data demonstrate a proof of concept, collagen gene supplementation for the gene therapy of OI will require, among other things, sustained transgene expression. One approach to therapy would include the harvest of osteoprogenitors from OI patients, followed by suppression of mutant allele expression. The silenced, mutant collagen gene would then be supplemented by transduction of the cells with the normal collagen gene with subsequent re-implantation of the cells into the OI patient ( Figure 5 ).
Gene targeting to bone
The hallmark of OI is bone fragility. Therefore, any successful gene therapy will require high collagen transgene expression in bone to normalize tissue function. In this situation, use of tissue-specific promoters will be helpful. As a proof of concept, Hou et al 63 used adherent murine bone marrow-derived mesenchymal Gene therapy and osteogenesis imperfecta C Niyibizi et al stem cells containing a reporter gene under the control of the osteocalcin promoter to restrict expression to bone. Analysis of the expression of the reporter gene demonstrated that the expression was restricted to osteoblasts and osteocytes. These data demonstrated that it is possible to restrict gene expression to specific tissues using tissue-specific promoters. Other bone-specific promoters will need to be evaluated, for example cbfa1 64 or the collagen a1(I) promoter.
Conclusion
The design of gene therapies targeting dominant negative mutations for OI is complex and will require a combination of different approaches for clinical application. The continual development of methods to silence gene expression will aid greatly in the development of gene therapy approaches. Effective gene therapy for OI will require suppression of mutant collagen alleles without affecting the normal endogenous allele. The highly heterogenous nature of OI mutations, however, necessitates development of mutation-independent strategies that would cover a wide spectrum of OI mutations. A combination of gene silencing and gene replacement approaches in stem cells will need to be developed for the treatment of OI patients with dominant-negative mutations. In addition, clear understanding of the nature of the stem cells for gene delivery to the skeleton, and of the engraftment characteristics of the cells, methods of cell delivery and methods to increase efficiency of the mesenchymal stem cell engraftment will need to be developed for the successful gene therapy for OI treatment.
